New drug targeting DNA repair shows promise in range of advanced cancers

September 28, 2020

A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial - highlighting the potential of a new class of drugs known as ATR inhibitors.

The drug candidate, tested in humans for the first time, was shown to be well tolerated and stopped the growth of tumours in over half of patients treated.

People in the trial had a range of advanced, heavily pre-treated cancers including breast, bowel and prostate tumours. It is remarkable to see the new drug - which works by blocking a key molecule called ATR, involved in repairing DNA - showing promising clinical benefit in a phase I trial, in patients who were very sick.

The trial, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, involved 21 patients with advanced solid tumours with defects in various genes which help coordinate DNA repair. Eleven patients had tumours with defects or deletions affecting a key gene called ATM.

The aim of the trial was to evaluate the safety of the ATR inhibitor BAY1895344 and to identify the maximum tolerated dose that could be safely given to a group of cancer patients who had already previously been treated with multiple other drugs.

The researchers found that the drug was well tolerated by patients - and better still, that there were encouraging signs that it was effective against advanced cancers with defects in the ATM gene.

The new results are published in the prestigious journal Cancer Discovery today (Tuesday), and the trial was funded by the manufacturer of the drug, Bayer.

The team found that BAY1895344 stopped tumour growth in eight out of the 21 patients and shrunk the tumours of another four patients with ATM mutations - which is remarkably positive for a phase I trial, since its primary aim is to test the safety of a drug, rather than its effectiveness.

The effectiveness of the drug seemed to be long lasting, with an average period of response of 316 days. In addition, three out of four patients who saw their tumours shrink remained on treatment for more than a year.

The most common side effect reported was anaemia, which was managed with the help of blood transfusions and did not usually require the treatment to be stopped.

The researchers also analysed the biochemical and pharmacological effects of the drug, and were able to show that it exercised its effects in patients by increasing damage to DNA.

DNA damage is the fundamental cause of cancer - leading to mutations in key genes that allow cancer cells to divide uncontrollably. But it can also be a key weakness of tumours that can be exploited, since cancer cells can be killed by further damaging their DNA or stopping them from repairing it.

The new study supports further investigation of a treatment strategy that targets the DNA repair protein ATR, especially in patients whose cancers already have certain defects in DNA repair genes like ATM or BRCA1 - weakening their ability to cope with DNA damage.

Further clinical trials are warranted to further evaluate the safety and efficacy before it can be licensed by a regulatory authority. Clinical trials investigating BAY 1895344 as a single agent or in combination with other drugs are now under way, and the hope is that it could be developed into a new targeted treatment for patients with a variety of cancers with certain defects in DNA repair.

Recently, another phase I trial led by The Institute of Cancer Research (ICR) and The Royal Marsden also showed benefits for an ATR inhibitor (called berzosertib) in patients with very advanced tumours, either on its own or with chemotherapy.

Other cancer drugs that attack DNA repair mechanisms already exist. The ICR pioneered the genetic targeting of the first approved precision medicine attacking cancer's ability to repair DNA, the PARP inhibitor olaparib.

In future, ATR inhibitors may become a new class of targeted drugs that could help overcome resistance to other precision medicines like PARP inhibitors.

The ICR, a charity and research institute, will be focusing on how to overcome drug resistance in its new Centre for Cancer Drug Discovery, which is nearing completion. The ICR is now raising money for the Centre's state-of-the-art equipment, so that researchers in the building can get off to the strongest possible start.

Study leader Professor Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said:

"Our new trial shows that this promising new treatment is safe and can benefit some patients even with very advanced cancers.

"The new drug, which is currently known only by the code BAY1895344, works by blocking a molecule called ATR which is involved in repairing DNA. It seems to be especially effective in patients whose tumours have defects in a gene called ATM which mean their ability to repair DNA is already weakened - suggesting that this could become a new form of targeted treatment.

"It is very promising to see patients responding in an early-stage trial like this, and we are looking forward to further clinical trials to test the drug's efficacy."

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

"It is exciting to see a new class of precision medicine showing such promise in early trials. At the ICR, we have pioneered ways of treating cancer by exploiting the weaknesses that tumours often have in repairing their DNA. I am hopeful that later-stage trials will show that this new class of ATR inhibitors can prove effective against cancers with defective systems for DNA repair, and we are keen to investigate whether they could prevent tumours from developing resistance to another important class of medicine called PARP inhibitors, which work in a similar way.

"One of our main goals is to find new targeted treatments and drug combinations that can tackle cancer evolution and drug resistance - and this will be the main focus of research in our pioneering new Centre for Cancer Drug Discovery."
Notes to editors

For more information please contact Diana Cano Bordajandi in the ICR press office on 020 7153 5021 or For enquiries out of hours, please call 07595 963 613.

The Institute of Cancer Research, London, is one of the world's most influential cancer research organisations.

Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top centres for cancer research and treatment globally.

The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it is a world leader at identifying cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

A college of the University of London, the ICR is the UK's top-ranked academic institution for research quality, and provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

The ICR's mission is to make the discoveries that defeat cancer. For more information visit

Institute of Cancer Research

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to